ArticleCureus2025
Pulse Oximetry Desaturation in the Postoperative Recovery Room in Patients with Obesity and Diabetes Using GLP-1 Agonists: A Retrospective Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perioperative Management of Patients using GLP-1 Receptor Agonists Current Evidence, Risks, and Practical Recommendations-A Narrative Review.Turkish journal of anaesthesiology and reanimation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesGlucagon-like peptide-1 agonists (GLP-1), obesity, and diabetes may delay gastric emptying in some settings. We tested three hypotheses. First, the duration of GLP1-hold is associated with a larger difference between pulse oximetry at room air immediately preoperatively and one hour postoperatively, just prior to discharge home (DSpO2), as a marker of clinically important atelectasis and/or micro-aspiration. Second, we tested the hypothesis that the duration of GLP1-hold affects fasting glucose. Third, we tested the hypothesis that DSpO2 is linked to morbid obesity. MATERIALS AND
methodsIn this retrospective observational cohort study, we screened the cohort of all 1571 patients undergoing urologic ambulatory surgery in one stand-alone center between September 2023 and September 2024. The inclusion criteria were diabetics using GLP-1 within 30 days, creatinine below 2 mg/dL, and age between 18 and 80 years. The outcomes of fasting glucose and DSpO2 were compared between the groups holding GLP-1 longer and shorter than seven days. The outcome DSpO2 was also compared between the groups with and without morbid obesity, defined generally as a body mass index (BMI) of over 35 kg/m² in the presence of one major comorbidity. All of our study subjects had diabetes mellitus, a major comorbidity.
resultsAmong all 107 subjects, 56% had laryngeal mask airways and 9% endotracheal tubes. GLP-1 was held 12 ± 8 days (mean ± SD). DSpO2 was 1.5% ± 1.9 with short GLP-1-hold versus 1.8% ± 2.0 with long GLP-1-hold (p=0.41). The mean glucose was 130 mg/dL ± 49 with short GLP1-hold versus 138 mg/dL ± 39 with long GLP-1-hold (p=0.69). DSpO2 was 2.29% ± 1.78 with morbid obesity (N=38) versus 1.43% ± 1.99 without (N=69, p=0.0254, unpaired two-tailed t-test). Patients with morbid obesity showed a trend toward twice the incidence (at 24%) for DSpO2 > 4% (chi-square, p=0.14).
conclusionsIt may be prudent to protect the airway with endotracheal intubation for patients with morbid obesity and diabetes using GLP-1, especially in the lithotomy position.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.